Should I buy or sell Plus Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Plus Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PSTV shares. View PSTV analyst ratings or view top-rated stocks .

What is Plus Therapeutics' stock price target for 2024?

1 analysts have issued 12 month price targets for Plus Therapeutics' shares. Their PSTV share price targets range from $8.00 to $12.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 509.8% from the stock's current price. View analysts price targets for PSTV or view top-rated stocks among Wall Street analysts .

How have PSTV shares performed in 2024?

Plus Therapeutics' stock was trading at $1.7501 on January 1st, 2024. Since then, PSTV shares have decreased by 6.3% and is now trading at $1.64. View the best growth stocks for 2024 here .

Are investors shorting Plus Therapeutics?

Plus Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 46,800 shares, an increase of 45.3% from the March 15th total of 32,200 shares. Based on an average daily trading volume, of 31,400 shares, the short-interest ratio is presently 1.5 days. Currently, 1.1% of the shares of the stock are short sold. View Plus Therapeutics' Short Interest .

How were Plus Therapeutics' earnings last quarter?

Plus Therapeutics, Inc. (NASDAQ:PSTV) released its earnings results on Tuesday, March, 5th. The company reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.08. The firm had revenue of $1.31 million for the quarter, compared to analysts' expectations of $1.26 million. Plus Therapeutics had a negative net margin of 271.04% and a negative trailing twelve-month return on equity of 805.57%.

When did Plus Therapeutics' stock split?

Plus Therapeutics's stock reverse split before market open on Monday, May 1st 2023. The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Plus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Plus Therapeutics investors own include Advanced Micro Devices (AMD) , Trevena (TRVN) , Chimerix (CMRX) , Genocea Biosciences (GNCA) , Sorrento Therapeutics (SRNE) , Akero Therapeutics (AKRO) , Aldeyra Therapeutics (ALDX) , Aileron Therapeutics (ALRN) and CymaBay Therapeutics (CBAY) .

How do I buy shares of Plus Therapeutics?

Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PSTV

Plus Therapeutics (PSTV) Stock Price, News & Analysis

→ Your Money is Not Safe (From American Alternative) (Ad)

Free PSTV Stock Alerts

$1.64

-0.05 (-2.96%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.63
▼
$1.77
50-Day Range: $1.63
▼
$2.18
52-Week Range: $0.97
▼
$5.09

Volume: 24,591 shs
Average Volume: 29,749 shs
Market Capitalization: $7.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Plus Therapeutics alerts:

Plus Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 509.8% Upside
$10.00 Price Target
Short Interest: Healthy
1.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.99) to ($1.03) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.70 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Plus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Plus Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.11% of the float of Plus Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Plus Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Plus Therapeutics has recently increased by 45.34%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Plus Therapeutics does not currently pay a dividend.
Dividend Growth
Plus Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PSTV.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Plus Therapeutics this week, compared to 1 article on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Plus Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.32% of the stock of Plus Therapeutics is held by insiders.
Percentage Held by Institutions
Only 3.28% of the stock of Plus Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Plus Therapeutics are expected to decrease in the coming year, from ($0.99) to ($1.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Plus Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Plus Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad American Alternative

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

CLICK HERE TO GET YOUR GUIDE NOW

About Plus Therapeutics Stock (NASDAQ:PSTV)

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

PSTV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PSTV Stock News Headlines

April 19, 2024 | finance.yahoo.com

Plus Therapeutics, Inc. (PSTV)

April 9, 2024 | finance.yahoo.com

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team

April 20, 2024 | American Alternative (Ad)

Your Money is Not Safe

April 9, 2024 | globenewswire.com

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.

March 27, 2024 | finance.yahoo.com

Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference

March 25, 2024 | finance.yahoo.com

Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

March 23, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds

March 11, 2024 | finance.yahoo.com

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

April 20, 2024 | American Alternative (Ad)

Your Money is Not Safe

March 7, 2024 | finance.yahoo.com

Plus Therapeutics Full Year 2023 Earnings: Beats Expectations

March 7, 2024 | finance.yahoo.com

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript

March 6, 2024 | finance.yahoo.com

Q4 2023 Plus Therapeutics Inc Earnings Call

March 5, 2024 | investorplace.com

PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023

March 5, 2024 | globenewswire.com

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

February 29, 2024 | msn.com

IMUNON stock rallies 19% on early results for COVID-19 vaccine

February 27, 2024 | finance.yahoo.com

Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024

February 21, 2024 | morningstar.com

Plus Therapeutics Inc PSTV

December 18, 2023 | finanznachrichten.de

Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024

December 18, 2023 | finance.yahoo.com

Plus Updates Financial and Cash Guidance for 2024

December 12, 2023 | finance.yahoo.com

Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses

November 29, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)

November 20, 2023 | msn.com

Fortress Biotech, Plus Therapeutics among healthcare movers

November 20, 2023 | finance.yahoo.com

Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar

November 15, 2023 | finance.yahoo.com

Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023

November 3, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Geron (GERN), Silk Road Medical (SILK) and Plus Therapeutics (PSTV)

November 3, 2023 | finance.yahoo.com

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases

November 1, 2023 | benzinga.com

Why Plus Therapeutics Stock Popped Today

See More Headlines

Receive PSTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:PSTV
CUSIP: N/A
CIK: 1095981
Web: www.plustherapeutics.com
Phone: 737-255-7194
Fax: 858-450-4335
Employees: 20
Year Founded: 1996

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $12.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +509.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($33.7590)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,320,000.00
Net Margins: -271.04%
Pretax Margin: -271.04%
Return on Equity: -805.57%
Return on Assets: -97.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.92
Quick Ratio: 0.92

Sales & Book Value

Annual Sales: $4.91 million
Price / Sales: 1.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.30) per share
Price / Book: -5.47

Miscellaneous

Outstanding Shares: 4,280,000
Free Float: 4,177,000
Market Cap: $7.02 million
Optionable: Not Optionable
Beta: 0.59

Social Links

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Marc H. Hedrick M.B.A. (Age 61)
M.D., President, CEO & Director
Comp: $945.34k
Mr. Andrew J. Sims CPA (Age 51)
VP of Finance & CFO
Comp: $498.51k
Dr. Norman D. LaFrance FACNP (Age 76)
FACP, M.D., Chief Medical Officer & Senior VP
Comp: $646.02k
Ms. Desiree Smith (Age 60)
Corporate Controller, Principal Financial & Accounting Officer
Dr. John K. Fraser (Age 63)
Chief Scientist

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PSTV Stock Analysis - Frequently Asked Questions

Should I buy or sell Plus Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Plus Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PSTV shares.
View PSTV analyst ratings or view top-rated stocks.
What is Plus Therapeutics' stock price target for 2024?: 1 analysts have issued 12 month price targets for Plus Therapeutics' shares. Their PSTV share price targets range from $8.00 to $12.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 509.8% from the stock's current price.
View analysts price targets for PSTV or view top-rated stocks among Wall Street analysts.
How have PSTV shares performed in 2024?: Plus Therapeutics' stock was trading at $1.7501 on January 1st, 2024. Since then, PSTV shares have decreased by 6.3% and is now trading at $1.64.
View the best growth stocks for 2024 here.
Are investors shorting Plus Therapeutics?: Plus Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 46,800 shares, an increase of 45.3% from the March 15th total of 32,200 shares. Based on an average daily trading volume, of 31,400 shares, the short-interest ratio is presently 1.5 days. Currently, 1.1% of the shares of the stock are short sold.
View Plus Therapeutics' Short Interest.

How were Plus Therapeutics' earnings last quarter?: Plus Therapeutics, Inc. (NASDAQ:PSTV) released its earnings results on Tuesday, March, 5th. The company reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.08. The firm had revenue of $1.31 million for the quarter, compared to analysts' expectations of $1.26 million. Plus Therapeutics had a negative net margin of 271.04% and a negative trailing twelve-month return on equity of 805.57%.
When did Plus Therapeutics' stock split?: Plus Therapeutics's stock reverse split before market open on Monday, May 1st 2023. The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Plus Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Plus Therapeutics investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Chimerix (CMRX), Genocea Biosciences (GNCA), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Aileron Therapeutics (ALRN) and CymaBay Therapeutics (CBAY).
How do I buy shares of Plus Therapeutics?: Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PSTV) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Plus Therapeutics (PSTV) Stock Price, News & Analysis

Plus Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About Plus Therapeutics Stock (NASDAQ:PSTV)

PSTV Stock Price History

PSTV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

PSTV Stock Analysis - Frequently Asked Questions

Overall MarketRank^™